Breast cancer is a common malignant tumor among women, with its prevalence ranking first among malignant diseases in women in our country, so attention is increasingly being paid to this disease. Regulatory T cells (Tregs) play an important role in breast cancer immune response, and the therapeutic strategy of targeting Tregs in breast cancer appears to have potential feasibility. In this paper, the authors address the issues in this field.